4.2 Article

Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data

Journal

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Volume 24, Issue 9, Pages 934-942

Publisher

WILEY
DOI: 10.1002/pds.3798

Keywords

antidepressant; pregnancy; effectiveness; administrative data; confounding; pharmacoepidemiolgy

Funding

  1. Agency for Healthcare Research and Quality [R01 HSO18533]
  2. National Institutes of Health [R01 AI102634, R01 MH100216]
  3. National Institute of Mental Health [K01 MH099141]

Ask authors/readers for more resources

PurposeThe decision whether to continue antidepressant use for depression during pregnancy requires weighing maternal and child risks and benefits. Little is known about the effectiveness of antidepressant therapy during pregnancy. The goal of this study is to evaluate whether standard administrative claims data can be used to evaluate the effectiveness of antidepressants. MethodsUsing prescription and healthcare visit Medicaid claims (2000-2007), we identified 28493 women with a depression diagnosis and antidepressant fill in the 90days before their last menstrual period. Antidepressant continuation was defined based on prescription fills during the first trimester. Depression hospitalizations and deliberate self-harm served as measures of the effectiveness of treatment continuation during pregnancy. Propensity score and instrumental variable analyses were used to attempt to account for confounding. ResultsRelative to women who discontinued antidepressant therapy, women who continued were more likely to have a depression inpatient stay (odds ratio [OR]=2.2, 95% confidence interval [95%CI]: 2.0-2.4) and deliberate self-harm code (OR=1.4, 95%CI: 0.7-2.7). Accounting for measured covariates in the propensity score analysis, including age, race, comorbidities, comedications, features of the depression diagnosis, and antidepressant class, led to slightly attenuated estimates (OR=2.0, 95%CI: 1.8-2.2; OR=1.1, 95%CI: 0.5-2.4). Similar associations were estimated in subgroups with different levels of baseline depression severity. Proposed preference-time, calendar-time-based, and geography-based instruments were unlikely to meet the required conditions for a valid analysis. ConclusionsOur findings suggest that either antidepressant medications do not reduce the risk of depression relapse in pregnant women, or that administrative data alone could not be used to validly estimate the effectiveness of psychotropic medications during pregnancy. Copyright (c) 2015 John Wiley & Sons, Ltd.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available